Medhealth Review

IIL Injects Rs 700 Crore into State-of-the-Art Vaccine Plant Addressing Livestock Diseases

Indian Immunologicals (IIL), operating under the National Dairy Development Board (NDDB), announced the initiation of constructing a new vaccine manufacturing plant in Genome Valley, Hyderabad. The company’s investment of approximately Rs 700 crore underscores its commitment to this facility.

READ MORE: New RSV Vaccine Created by Pfizer Could Be Very Effective

Designed with a Biosafety Level 3 (BSL3) for drug substance production and Fill-Finish capability for final vaccine products, the plant focuses on addressing two significant livestock diseases: Foot and Mouth Disease (FMD) and Haemorrhagic Septicaemia (HS). With an annual capacity of 150 million doses for each vaccine, totaling 300 million doses, the facility holds substantial promise in combating these diseases.

READ MORE: Free Covid Vaccines are Available Even Without Insurance If No Government Supply

This development foresees the creation of over 750 direct and indirect job opportunities. Positioned strategically within Genome Valley, the facility aligns Indian Immunologicals at the heart of India’s biotechnology epicenter. This further cements Hyderabad’s standing as a global leader in vaccine innovation and production.

Meenesh Shah, NDDB’s Chairman, emphasized the facility’s significance, affirming Indian Immunologicals’ commitment to eradicating FMD and HS within the nation. K Anand Kumar, IIL’s Managing Director, echoed this commitment, anticipating a 40% growth surge this year. Kumar sees this facility as a catalyst for additional investments, contributing significantly to disease control efforts in India and emerging markets.

The launch of Indian Immunologicals’ advanced vaccine manufacturing plant heralds a significant stride in combating livestock diseases. With a robust capacity and strategic placement in Genome Valley, Hyderabad, this initiative not only promises to address Foot and Mouth Disease (FMD) and Haemorrhagic Septicaemia (HS) but also signifies a major boost for job creation and India’s biotechnology prominence. The dedication expressed by NDDB’s Chairman, Meenesh Shah, and IIL’s Managing Director, K Anand Kumar, underscores a collective commitment toward disease eradication and future advancements in vaccine production, positioning the facility as a cornerstone in India’s fight against livestock diseases and a beacon for global biotechnological innovation.

Must Read
Related Articles